Bisoprolol Shortage: What Providers and Prescribers Need to Know in 2026

Provider Briefing: Bisoprolol Availability in 2026

If your patients are reporting difficulty filling Bisoprolol prescriptions, you're not imagining a trend. While Bisoprolol Fumarate is not currently listed on the FDA's drug shortage database, real-world pharmacy availability has been inconsistent — particularly at large chain pharmacies in the United States.

This briefing provides an evidence-based overview of the current supply landscape, prescribing considerations, therapeutic alternatives, and tools that can help both you and your patients navigate the situation.

Current Status: Supply vs. Stocking

As of Q1 2026, the distinction between a supply shortage and a stocking gap is critical:

• FDA Shortage Database: Bisoprolol is not listed as being in shortage
• ASHP Shortage List: Bisoprolol is not listed
• Manufacturer status: Generic Bisoprolol Fumarate (5 mg and 10 mg tablets) continues to be produced by multiple manufacturers including Sandoz, Teva, and others
• Wholesale availability: Major distributors (McKesson, Cardinal Health, AmerisourceBergen) report Bisoprolol as orderable

The disconnect is at the pharmacy shelf level. Because Bisoprolol represents a small fraction of US beta-blocker prescriptions — far behind Metoprolol and Atenolol — many retail pharmacies do not maintain active stock. This creates a perception of shortage that, for the patient standing at the counter, is functionally real.

Timeline of Availability Patterns

Bisoprolol's availability challenges in the US are not new and reflect long-standing prescribing patterns rather than acute supply disruptions:

• 2010s: Zebeta (brand) discontinued; market transitions fully to generic. US prescribing volume remains modest compared to European markets where Bisoprolol (often as Concor) is a first-line agent.
• 2020-2023: COVID-era supply chain disruptions created intermittent availability issues across many cardiovascular generics. Bisoprolol experienced localized disruptions but was not placed on formal shortage lists.
• 2024-2026: Supply chain has normalized, but pharmacy stocking patterns have not fully recovered for lower-volume generics. Automated inventory systems at chain pharmacies continue to deprioritize Bisoprolol.

Prescribing Implications

When to Maintain Bisoprolol

There are clinical scenarios where continuing Bisoprolol is strongly preferred:

• Patients stable on Bisoprolol for HFrEF: Bisoprolol is one of only three beta-blockers with guideline-directed evidence for reducing mortality in heart failure (alongside Metoprolol Succinate and Carvedilol). Switching a stable patient introduces unnecessary risk.
• Patients with COPD or reactive airway disease: Bisoprolol's high beta-1 selectivity makes it a preferred choice. Switching to a less selective agent could precipitate bronchospasm.
• Patients who have failed or are intolerant of alternatives: Some patients experience significant fatigue, metabolic effects, or bradycardia with Metoprolol or Carvedilol but tolerate Bisoprolol well.

When Switching May Be Appropriate

• New-start patients where Bisoprolol availability is uncertain in their area
• Patients unable to reliably access Bisoprolol despite trying multiple pharmacies and mail-order
• Clinical scenarios where an alternative is equally appropriate (e.g., hypertension without heart failure)

Equivalent Dosing Reference

If switching is clinically indicated, approximate dose equivalencies for common alternatives:

• Bisoprolol 5 mg ≈ Metoprolol Succinate 50 mg daily
• Bisoprolol 10 mg ≈ Metoprolol Succinate 100 mg daily
• Bisoprolol 5 mg ≈ Carvedilol 12.5 mg twice daily
• Bisoprolol 10 mg ≈ Carvedilol 25 mg twice daily
• Bisoprolol 5 mg ≈ Atenolol 50 mg daily (hypertension only; not for HFrEF)

These are approximate equivalencies. Individual patient response varies. Monitor blood pressure and heart rate closely during any transition.

The Availability Picture: Where Patients Can Find Bisoprolol

When patients report they "can't find" Bisoprolol, it's worth helping them explore options beyond their usual pharmacy:

Independent Pharmacies

Independent pharmacies are significantly more likely to order Bisoprolol on request and can typically obtain it from wholesalers within 1-2 business days.

Mail-Order Pharmacy

Mail-order services (insurance-linked or independent options like Cost Plus Drugs, Amazon Pharmacy) provide 90-day supplies and have broader generic inventory.

Pharmacy Availability Tools

Medfinder for Providers offers a real-time pharmacy availability search that can identify which local pharmacies have Bisoprolol in stock. This can be a useful resource for your care team when coordinating with patients.

Cost and Access Considerations

Bisoprolol's cost profile is favorable for patients:

• Generic cash price: $30-$55 per 30 tablets (retail)
• With discount cards: $10-$15 per month (GoodRx, SingleCare)
• Insurance: Tier 1 preferred generic on most commercial and Medicare Part D plans; typical copay $0-$10
• No prior authorization required on most formularies
• No manufacturer savings program (brand discontinued; generic-only market)

For patients experiencing financial hardship, resources like NeedyMeds (needymeds.org) and RxAssist (rxassist.org) can help identify patient assistance options.

Tools and Resources for Your Practice

• Medfinder for Providers — real-time pharmacy stock search; share with patients or use at point of care
• FDA Drug Shortage Database (accessdata.fda.gov/scripts/drugshortages) — monitor formal shortage status
• ASHP Drug Shortage Resource Center (ashp.org/drug-shortages) — clinical alternatives and management guidelines
• GoodRx/SingleCare — direct patients to these free discount programs when insurance copays are high or for uninsured patients

Consider providing your patients with a printed guide or directing them to our patient-facing article: How to Find Bisoprolol in Stock Near You.

Looking Ahead

Bisoprolol's position in the US market is unlikely to change dramatically in the near term. It will remain a lower-volume generic with intermittent stocking challenges at retail pharmacies. However, the drug is well-manufactured, affordable, and therapeutically valuable — particularly for HFrEF and in patients where high beta-1 selectivity is clinically important.

The most effective strategy is proactive planning: help patients identify reliable pharmacy sources, use availability tools, and reserve therapeutic switching for situations where access genuinely cannot be resolved.

For a complete provider workflow for managing patients on hard-to-find medications, see our companion guide: How to Help Your Patients Find Bisoprolol in Stock.

Final Thoughts

The Bisoprolol availability challenge is a distribution problem, not a supply problem. With the right tools and a proactive approach, most patients can maintain their current regimen without disruption. As providers, the best thing we can do is equip patients with the resources to find their medication — and reserve therapeutic changes for cases where access truly cannot be resolved.

Medfinder for Providers is a free tool designed to help with exactly this kind of challenge.